- Home
- GRX vs UNCY Comparison
GRX vs UNCY Comparison
Compare GRX & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GRX | UNCY |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.9M | 145.3M |
| IPO Year | 2007 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GRX | UNCY |
|---|---|---|
| Price | $9.07 | $7.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $25.67 |
| AVG Volume (30 Days) | 19.8K | ★ 539.6K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $675,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $582.86 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.93 | $0.47 |
| 52 Week High | $10.05 | $7.78 |
Technical Indicators
Market Signals| Indicator | GRX | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 40.16 | 53.00 |
| Support Level | $8.93 | $5.95 |
| Resistance Level | $9.35 | $7.32 |
| Average True Range (ATR) | 0.12 | 0.35 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 2.93 | 49.61 |
Price Performance
Historical ComparisonAbout GRX The Gabelli Healthcare & Wellness Trust of Beneficial Interest
Gabelli Healthcare & WellnessRx Trust operates as a diversified closed-end management investment company. The investment objective of the fund is the long-term growth of capital. The fund invests at least its assets in equity securities and income-producing securities of domestic and foreign companies in the healthcare and wellness industries. It invests in various sectors, of which Health Care Providers & Services, Food, Health Care Equipment and Supplies, and Pharmaceuticals account for the majority of the weightage.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.